Asunto(s)
Neoplasias Gastrointestinales/etiología , Neoplasias Gastrointestinales/microbiología , Infecciones por Helicobacter/complicaciones , Helicobacter pylori/fisiología , Células de la Médula Ósea/microbiología , Células de la Médula Ósea/patología , Disbiosis/complicaciones , Disbiosis/microbiología , Disbiosis/patología , Microbioma Gastrointestinal , Neoplasias Gastrointestinales/patología , Infecciones por Helicobacter/microbiología , Infecciones por Helicobacter/patología , Humanos , Células Madre/microbiología , Células Madre/patologíaAsunto(s)
Infecciones por Helicobacter , Helicobacter pylori , Microbiota , Gastropatías , Disbiosis , HumanosAsunto(s)
Transformación Celular Neoplásica/patología , Colon/microbiología , Infecciones por Helicobacter/fisiopatología , Helicobacter pylori/patogenicidad , Adenoma/metabolismo , Adenoma/microbiología , Estudios de Casos y Controles , Transformación Celular Neoplásica/metabolismo , Colon/metabolismo , Neoplasias Colorrectales/metabolismo , Neoplasias Colorrectales/microbiología , Humanos , Receptores de Hialuranos/metabolismoRESUMEN
Although degenerative diseases of the central nervous system, including Alzheimer's disease (AD), have an increasingly high impact on aged population their association with Helicobacter pylori (H. pylori) infection has not as yet been thoroughly researched. Current H. pylori infection appears to induce irregular humoral and cellular immune responses that, owing to the sharing of homologous epitopes (molecular mimicry), cross-react with components of nerves, thereby contributing and possibly perpetuating the apoptotic neural tissue damage observed in neurodegenerative diseases including AD. An association between AD and H. pylori infection has been recently addressed by two studies. A higher seropositivity for anti-H. pylori immunoglobulin G antibodies in 30 patients with AD than in 30 age-matched controls was reported in one study; this serological test, however, has limitations because it does not discriminate between current and old infections. In the other study, by introducing the histological method (the actual gold standard) for diagnosis of H. pylori infection, we reported a higher prevalence of H. pylori infection in 50 AD patients than in 30 anemic controls. This pathogen may influence the pathophysiology of AD by promoting platelet and platelet-leukocyte aggregation; releasing various pro-inflammatory and vasoactive substances; developing cross-mimicry with host antigens; producing reactive oxygen metabolites and circulating lipid peroxides; influencing the apoptotic process; and increasing, through induction of atrophic gastritis, homocysteine, which contributes to vascular disorders implicated in endothelial damage and neurodegeneration.
Asunto(s)
Enfermedad de Alzheimer/etiología , Infecciones por Helicobacter/complicaciones , Helicobacter pylori , Enfermedad de Alzheimer/inmunología , Enfermedad de Alzheimer/microbiología , Anticuerpos Antibacterianos/análisis , Apoptosis , Infecciones por Helicobacter/inmunología , Humanos , Inmunoglobulina G/análisisRESUMEN
BACKGROUND/AIMS: Limited data exist concerning infliximab administration in steroid-dependent ulcerative colitis (UC) patients. The aim of this study was to evaluate the efficacy and safety of infliximab in steroid-dependent disease. METHODOLOGY: Sixteen corticosteroid-dependent patients who received infusions of infliximab (5 mg/kg) at 0, 2 and 6 weeks and thereafter every 8 weeks (Group A), were compared with eight patients treated with methylprednisolone (0.8-1 mg/kg body weight) daily for three weeks followed by a tapering regimen up to the minimal dose to maintain a symptom-free condition (Group B). Steroid dependency was defined as recurrent flare-up on steroid reduction or withdrawal, or as the clinical need for steroid treatment twice within six consecutive months or three times within a year. Disease activity was assessed at recruitment, and clinical response was evaluated according to the two non-invasive indices [SEO and Simple Clinical Colitis Activity Index (SCCAI) scores]. RESULTS: In Group A, complete long-term response occurred in 68.75% and partial response in 18.75% of patients. Moreover, in the long-term follow-up, both SCCAI (10.37 +/- 2.27 vs. 3.31 +/- 2.65, p < 0.001) and SEO (209.33 +/- 13.6 vs. 123.3 +/- 34.8, p < 0.001) scores demonstrated a significant improvement. In group B, comparable features were also obtained regarding complete long-term (62.5%) and partial (25%) responses; both SCCAI (7.37 +/- 1.4 vs. 3.5 +/- 3.58, p = 0.039) and SEO (181.0 +/- 27.1 vs. 135.3 +/- 44.1, p = 0.038) scores also improved significantly. Six of eight patients in the methylprednisolone-treated group B developed Cushing-like symptoms. CONCLUSIONS: Infliximab appears to be a good alternative therapeutic regimen in steroid-dependent UC patients associated with long-term potential toxicity.